Excessive bleeding, a troublesome side-effect that causes many women to stop taking hormone replacement therapies (HRT), is less likely with progesterone than with more commonly used synthetic versions.
Results from a national clinical trial published in the November issue of the Journal of Obstetrics and Gynecology, show that a combination of estrogen and micronized progesterone (MP) causes fewer days and less intense bleeding than the most commonly used combination.
Previous studies have shown that unacceptable bleeding is the reason that most women discontinue HRT during the first year of therapy. Estrogen plus MP is a different combination therapy than estrogen plus medroxyprogesterone acetate (MPA), the most widely-used HRT.
Continuous estrogen plus MPA was used in the Women’s Health Initiative study which recently found that this form of HRT increased the risk of breast cancer, heart attack and stroke. While MPA is a strong synthetic compound that mimics the action of progesterone, MP is chemically and functionally identical to the progesterone that women naturally make before menopause.
Progestogens like MP and MPA are used to prevent problems that can develop in the uterus when estrogen is used by itself. MP is just as effective as MPA for that purpose.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!